Intercept Pharmaceuticals Inc (ICPT): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Intercept Pharmaceuticals ( ICPT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Intercept Pharmaceuticals rose $27.04 (7.1%) to $406.11 on light volume. Throughout the day, 608,516 shares of Intercept Pharmaceuticals exchanged hands as compared to its average daily volume of 822,400 shares. The stock ranged in a price between $378.01-$414.99 after having opened the day at $380.86 as compared to the previous trading day's close of $379.07. Other companies within the Drugs industry that increased today were: Anika Therapeutics ( ANIK), up 33.2%, Amyris ( AMRS), up 26.4%, Prana Biotechnology ( PRAN), up 19.9% and Cormedix ( CRMD), up 14.2%.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing its proprietary bile acid chemistry. Intercept Pharmaceuticals has a market cap of $7.2 billion and is part of the health care sector. Shares are up 446.5% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Intercept Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

On the negative front, Cerus Corporation ( CERS), down 17.2%, InterMune ( ITMN), down 14.9%, Biocryst Pharmaceuticals ( BCRX), down 7.6% and Jazz Pharmaceuticals ( JAZZ), down 7.4% , were all laggards within the drugs industry with Celgene Corporation ( CELG) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Emerging Markets Get Pounded by Trade War Concerns

Emerging Markets Get Pounded by Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

Dow Tumbles, Stocks Slide on Renewed Trade War Concerns

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Tesla Slumps After Mary McCormack Tweets Husband's Flaming Model S

Stocks Dive Globally as U.S.-China Trade War Intensifies

Stocks Dive Globally as U.S.-China Trade War Intensifies